Clinical Trial Update: Safety and Immunogenicity of Vi-CRM197 Vaccine Against S. Typhi in Children, Older Infants and Infants [Phase 2]

View source ↗

Summary

This Phase 2 trial evaluated the safety and immunogenicity of the Vi-CRM197 typhoid vaccine in infants and young children. The results were posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Typhoid Fever

Drugs mentioned

• Vi-CRM197 vaccine (Vi-CRM197 conjugate vaccine)

Snippet

Sponsor: Novartis | Conditions: Typhoid Fever | Phase 2 | Status: COMPLETED | Results posted: 2014-04-10